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ABSTRAK 
 
Sel-sel stem leukemia mempunyai pelbagai potensi diferensiasi. Imunofenotip sel 
leukemia biasanya konsisten sepanjang riwayat penyakit walaupun pada peristiwa 
kambuh. Jarang-jarang sekali, sel leukemia mungkin mengalami 'lineage switch' 
terutamanya pada saat kambuh. Kami ingin menyoroti kes tersebut pada seorang 
kanak-kanak lelaki berusia 10 tahun yang mengalami kelesuan, hilang selera makan, 
demam, gangguan pernafasan, kegagalan jantung, edema dan hepatosplenomegali 
selama dua minggu. Keputusan darah menunjukkan jumlah leukosit 41.5x109/l dan 
platelet 37x109/l. Filem darah periferi dan sampel aspirasi sumsum tulang 
menunjukkan kehadiran sel leukemia dalam kuantiti yang banyak. Sel-sel itu 
mempunyai nisbah nukleus kepada sitoplasma yang tinggi. Imunofenotip dan 
sitokemia menunjukkan keputusan yang konsisten dengan diagnosis T-sel leukemia 
limfoblastik akut. Pesakit mencapai remisi selepas dirawat dengan kemoterapi rejim B 
‘UK ALL 97 protocol’. Namun, penyakitnya kambuh tujuh bulan selepas itu dengan 
kehadiran sel leukemia sebanyak 26% di dalam sampel aspirat sumsum tulang. 
Majoriti adalah sel leukemia jenis L1 bercampur dengan minoriti sel leukemia jenis L2.  
Imunofenotip konsisten dengan leukemia prekursor B limfoblastik akut. Rawatan 
ditukar kepada kemoterapi yang lebih khusus, namun, pesakit tidak mencapai remisi 
dan kemudiannya rawatannya ditukar kepada kemoterapi paliatif. Kes ini 
mengilustrasikan kes 'lineage switch'  awal dari T-sel limfoblastik leukemia akut 
kepada leukemia prekursor B limfoblastik akut. 
 
Kata kunci:  ‘lineage switch’ awal, T-limfoblastik leukemia akut, B-limfoblastik 
leukemia akut 
 
 
ABSTRACT  
 
Leukaemic stem cells have heterogenous differentiation potential. The 
immunophenotypes of blast cells are usually consistent throughout the disease course 
even at relapse.  Rarely, blast cells may undergo a ‘lineage switch’ during the course 
of disease especially during relapse. We would like to highlight such a case in a 10-
year old boy who presented with a two weeks history of lethargy, poor appetite, low 
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grade fever, respiratory distress, cardiac failure, generalized oedema and 
hepatosplenomegaly. Full blood count showed a leucocyte count of 41.5x109/L and 
platelet count of 37x109/L. The peripheral blood film showed presence of numerous 
blast cells. Bone marrow aspiration revealed a hypercellular marrow, which consisted 
of mainly blast cells with high nuclear to cytoplasmic ratio and inconspicuous nucleoli. 
Immunophenotyping and cytochemistry results were consistent with the diagnosis of T-
cell acute lymphoblastic leukaemia. The patient achieved remission after treatment 
with UK ALL 97 protocol, regime B chemotherapy. However, he relapsed seven 
months after the initial diagnosis with 26% blast cells in the bone marrow aspirate. The 
majority was L1 blast cells admixed with some L2 blast cells. Immunophenotyping was 
consistent with common precursor B acute lymphoblastic leukaemia. The treatment 
was changed to a more lineage specific chemotherapy. Nonetheless, the patient never 
achieved remission and was planned for palliative management. This case illustrated a 
unique and rare case of rapid lineage switch from T-cell acute lymphoblastic leukaemia 
to common precursor B-cell acute lymphoblastic leukaemia. 
 
Key words:  early lineage switch, T-acute lymphoblastic leukaemia, B- acute  
  lymphoblastic leukaemia 
 
 
 
INTRODUCTION  
 
Acute lymphoblastic leukaemia (ALL) is 
one of the common malignancies of the 
pediatric age group. It results from clonal 
proliferation of lymphoid precursors with 
arrested maturation. The disease can 
originate from lymphoid cells of B- or T- 
lineage, although mixed lineage leukae-
mias do rarely occur. Its classification is 
based on morphological and cytochemi-
cal characteristics established by the 
French-American-British (FAB) group 
(Bennett et al. 1981). Today, the diagno-
sis of ALL is further facilitated by flow 
cytometry. Flow cytometric analysis al-
lows for sub-classification of ALL by uti-
lizing flourochrome-labelled monoclonal 
antibodies. About 60% of ALL patients 
have early pre-B immunophenotype. The 
blast cells usually express CD 19, 
cytoplasmic CD 22, CD 79α, CD 10, 
terminal deoxynucleotidyl transferase 
(TdT) and 75% express CD 34. T-cell 
ALL accounts for 12-15% of ALL cases. 
The blast cells express surface CD 7, 
cytoplasmic CD 3, CD 2, CD 5 and TdT.  
 
 
The blast cells may also express 
aberrant antigens which do not belong to 
the main lineage.  Immunological 
characterization of acute leukaemia is 
therefore essential in defining cell lineage 
to aid treatment options and 
determination of prognosis.  
The lineage of the leukaemic blast 
usually remains similar throughout the 
disease course, although the pattern of 
antigen expressions may change slightly.  
However, a switch of lineage of blast 
cells does rarely occur. Pui et al. 
described cases which showed switch 
from lymphoid to myeloid phenotype or 
the reverse (Pui et al. 1986). From 
literature review, phenotypic lineage 
switch rarely occurs from T-ALL to B-ALL 
or vice versa and to the best of our 
knowledge, only one case has described 
this phenomenon (Besalduch et al. 
1990). Our case illustrates an unusual 
phenotypic switch in leukaemic cells from 
a patient who first presented with T-cell 
acute lymphoblastic leukaemia who had 
gone into remission and relapsed seven 
months later with common pre-B ALL.  
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CASE REPORT 
 
A 10-year-old boy presented with two 
weeks history of low grade fever, lethargy 
and poor appetite. The patient was the 
youngest of four siblings. His father, a 
36-year-old man worked as a printing 
officer at a private company and his 
mother, a 36-year-old woman, was a 
housewife. 
At presentation, the patient was pale 
and in respiratory distress. His blood 
pressure was 105/40 mmHg, pulse rate 
of 168 bpm and oxygen saturation was 
100% under nasal prong oxygen. Physi-
cal examination revealed pleural effusion 
over the right lung and cardiomegaly.  
There were hepatosplenomegaly mea-
suring 5 cm and 4 cm below the subcos-
tal margins respectively. 
Laboratory investigation results showed 
haemoglobin (Hb) 4.9 g/dL, total white 
blood cells (WBC) 41.5x109/l, platelets 
37x109/l, neutrophils 0.8x109/l, lym-
phocytes 38.6x109/l. The peripheral 
blood smear showed presence of numer-
ous blast cells. The blast cells exhibited 
high nuclear to cytoplasmic ratio with in-
conspicuous nucleoli (Figure 1). 
His chest radiograph showed cardi-
omegaly with mediastinal widening. The 
bone marrow aspirate showed presence 
of more than 90% blast cells which were 
homogenous in size, showing high nuc-
lear to cytoplasmic ratio with basophilic 
cytoplasm and inconspicuous nucleoli. 
Other cell lines were depressed. The 
blast cells were negative for peroxidase 
and periodic acid Schiff stains. These 
findings were consistent with acute lym-
phoblastic leukaemia, FAB-L1. The tre-
phine biopsy showed similar findings.  
Flow cytometric analysis of the peripheral 
blood and bone marrow aspirate showed 
that the population was positive for T-cell 
markers; CD 2, intracellular CD 3, CD 4, 
CD 5, CD 7, CD 8, HLA-DR but negative 
for CD 19, CD 79a, CD 56, CD 117, intra 
MPO, CD 13 and CD 33 (Figure 2). Mar-
row cytogenetic study revealed a 46 XY 
normal karyotype with negative BCR-ABL 
translocation. 
The patient achieved remission with UK 
ALL 97 protocol regime B induction che-
motherapy.  However, at week 20, his 
bone marrow aspirate revealed presence 
of excess blast cells of 10%. Flow cyto-
metry analysis was inconclusive due to 
sample inadequacy. He subsequently 
received Doxorubicin, Vincristine, Dex-
amethasone and Asparaginase as per 
delayed intensification 1 chemotherapy 
protocol which was complicated by bron-
chopneumonia secondary to febrile neu-
tropaenia. The repeat bone marrow ex-
amination at week 25 showed persis-
tence of excess of blast cells (7%). The 
bone marrow examination was repeated 
at week 29 and showed presence of 
more than 26% blast cells which com-
prised of two populations of blast cells 
(Figure 3). One population was larger 
with abundant basophilic cytoplasm 
(morphologically L2 blast cells) while the 
other population was smaller, more ho-
mogenous with very scanty cytoplasm 
(L1 blast cells). The two populations of 
blast cells showed variable antigen ex-
pressions. Both populations of blast cells 
expressed CD 19, anti-HLA-DR, CD 10 
and cytoplasmic CD 22. One population 
of blast cells was CD 34 positive with 
negative CD 20 while the other popula-
tion was CD 34 negative with positive 
cytoplasmic CD 20. The blast cells were 
negative for intra CD 3, CD 7, CD 117, 
intra-MPO, CD 13 and CD 33 (Figure 4). 
A diagnosis of precursor B-cell acute 
lymphoblastic leukaemia with CD 10 
positivity (CALLA) was then made and 
the patient was started on the German 
Relapse Protocol (GRP). Repeat bone 
marrow examination after four months of 
relapse showed excess of blast cells 
(10%). The blast cells were mostly large 
in size with relatively abundant cytop-
lasm. A second course of chemotherapy 
was given for eight days. 
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Figure 1: Peripheral blood film of the patient showed presence of numerous blast cells with high 
nuclear:cytoplasmic ratio and inconspicuous nucleoli (arrow). (Wright stain, x 200) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Flow cytometric analysis of the bone marrow sample showed a single population of blast cells (red) 
expressing CD 3, CD 7, CD 4 and CD8 but negative for CD 34 and B-markers. 
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Figure 3: Bone marrow aspirate at relapse showed numerous blast cells. Some of the blast cells were large 
with relatively more cytoplasm (arrows) while the other blast cells were small with scanty cytoplasm (arrow 
heads).  (MGG, x 400)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Flow cytometric analysis of the patient’s bone marrow aspirate  showing two blast cell populations, 
one expressed CD 34 and negative for CD 20 surface markers (red population), while the other expressed 
CD 20 but negative for CD 34 yellow population.  However, both blast cell populations expressed HLA-DR, 
CD 10, CD 19 (dot plot not shown) and cytoplasmic CD 22. 
 
 
Review of bone marrow examination 
after completing two courses of chemo-
therapy showed persistence of blast cells 
(10% blast cells).  In view of this condi-
tion, bone marrow transplant was no 
longer a therapeutic option. The man-
agement was then changed to palliative 
care which included low-dose chemothe-
rapy and prophylactic treatment for infec-
tions. 
DISCUSSION 
 
Leukaemic stem cells have heterogenous 
differentiation potential.  It has been well 
described in various articles that many 
different patterns of inappropriate ex-
pression of lineage markers were ob-
served in acute leukaemias. The spec-
trum of mixed acute leukaemias includes 
biphenotypic leukaemia with markers of 
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more than one lineage of antigen expres-
sions present on the same blast cells, 
bilineal leukaemia with two distinct pop-
ulations, and biclonal leukaemia with two 
distinct leukaemic cells of independent 
origins (Hoffbrand et al. 1988). These 
terms have recently however been re-
vised in the WHO classification 2008.  
The term mixed phenotypic acute leu-
kaemia (MPAL) is now applied to both 
biphenotypic and bilineal leukaemia in 
general, with more specific terms 
B/myeloid (B/MY) and T/myeloid (T/MY) 
leukaemia which refer to leukaemias 
containing the lineages specified, irres-
pective of whether one or more than one 
population of blast cells is seen (Borowitz 
et al. 2008). There are cases of MPAL 
based on one criterion at diagnosis (e.g 
biphenotypic leukaemia) which change 
over time at relapse to the other (bilineal 
leukaemia), or vice versa. Furthermore, 
following therapy, persistent disease or 
relapse may occur as either pure ALL or 
AML. In some cases, this phenomenon 
has been termed ‘lineage switch’.  
The phenotypes of blast cells from pa-
tients with ALL upon relapse most often 
adhere to the original lineage (Greaves et 
al. 1980). However, blast cells which un-
dergo a ‘lineage switch’ during the course 
of disease especially during relapse had 
been estimated in some series to be as 
high as 8% (Stass et al. 1986). In this 
case, a phenotypic lineage switch is seen 
where the blast cells initially expressed 
T-cell markers (cytoCD3+, CD2+, CD4+, 
CD8+, CD5+, CD7+) at diagnosis. How-
ever at relapse, the blast cells were posi-
tive for B-cell markers (CD19+, in-
traCD22 and CD20) and also showed 
positivity towards CD10, CD34, HLA-DR 
but negative for cytoplasmic CD3, CD7, 
CD117 and anti-MPO. 
The mechanism of lineage switch re-
mains unclear. Most cases demonstrated 
consistent chromosomal findings at the 
time of diagnosis and switch and were 
therefore thought to be clonal in origin 
(Stass et al. 1984, Mantadakis et al. 
2007). It was hypothesized that chemo-
therapy might have induced suppression 
of a clone apparent at diagnosis, allowing 
the expansion of another clone with dif-
ferent markers, which was resistant to 
treatment (Stass et al. 1984). Alterna-
tively, the therapy might have a leuke-
mogenic effect on a normal hemopoietic 
cell and the lineage switch might then 
represent the induction of a new malig-
nancy rather than transformation of the 
initial leukaemic cells. In support of this 
view, there were cases described with a 
complete variation of cytogenetic mark-
ers at diagnosis and relapse (Park et al. 
2011) and after allogenic bone marrow 
transplantation (Brito-Babapulle et al. 
1989). However, therapy-induced acute 
leukaemia had a long latency period of 
about 69 months as described in a large 
multicentre GIMEMA trial reported by 
Pagano et al. in 1998. 
As in this case, there was a rapid li-
neage switch with an interval of just 
seven months from first presentation to 
relapse. As the time frame was too short, 
it was very unlikely for secondary malig-
nancy to have set in. Thus, the most 
likely pathogenesis for the lineage switch 
in this case was chemotherapy-induced 
suppression of the apparent leukaemic 
clone at diagnosis, while allowing the ex-
pansion of another clone with different 
markers which was resistant to treat-
ment. A similar conclusion was also 
reached by Shivarov et al. who reported 
a very early onset lineage switch from B-
ALL to AML in an adult patient within a 
period of only 3 months after the initial 
diagnosis (Shivarov et al. 2009). 
A variety of genetic anomalies has 
been reported in cases of ambiguous 
lineage leukaemias especially mixed 
phenotype acute leukaemia. The 
t(9;22)(q34;q11) BCR-ABL1 translocation 
and translocations associated with the 
MLL gene are the two most common ge-
netic anomalies associated with MPAL. 
Early Lineage Switch from T-to B-ALL  Med & Health 2011; 6(2): 131-138 
137 
 
In the case of lineage switch, the data 
are scanty, but two cases have been re-
ported to involve t (9;22)(q34;q11) BCR-
ABL1 translocation in two cases of Ph+ 
ALL to Ph+AML (Pane et al. 1996, Rear-
don et al. 1994). 
In a study of immunophenotypic and 
cytogenetic changes at relapse by Hur et 
al. in 2001, of  99 patients, 51 patients 
(51.5%) had immunophenotypic changes 
at relapse with expression of aberrant 
markers to be more frequent at relapse 
than at initial diagnosis especially in B 
lineage ALL (41.1% versus 10.3%). Cy-
togenetic changes at relapse were ob-
served in 28 of 46 patients (60.8%). The 
initial abnormal karyotypes were more 
frequently associated with clonal 
changes at relapse compared to initially 
normal karyotypes (78% versus 43%) 
(Hur et al. 2001).  
Loss of CD10 and other antigens at re-
lapse has been reported in about 15% of 
ALL patients, however a complete 
change of phenotype from T-cell ALL to 
B-cell ALL is rare. From literature search, 
only one case in 1990 had the same 
phenomenon. Besalduch et al. in 1990 
described a case of a 17-year old boy 
who first presented with massive hepa-
tosplenomegaly and a mediastinal mass 
and was diagnosed to have T-cell acute 
lymphoblastic leukaemia. He was given 
standard chemotherapy and achieved 
remission. However, he relapsed 4 years 
later as precursor B-ALL.  
In a study by Stass et al. in a series of 
264 newly diagnosed  acute leukaemia, 
of  the 239 patients who attained com-
plete remission, 89 relapsed with six 
cases (6.7%) demonstrating lineage 
switch from acute lymphoblastic leukae-
mia to acute myeloid leukaemia or vice 
versa. Of the six cases, four had T-cell 
associated characteristics either at diag-
nosis (three cases) or at lineage conver-
sion (one case) suggesting that T lym
phoblasts may have the potential for 
myeloid differentiation or that there may 
be a multipotential progenitor cell capa-
ble of both T lymphoblast and myeloblas-
tic differentiation. Of 30 patients with T-
ALL at diagnosis, 10 of the 89 patients 
who relapsed had T-cell ALL. Thus, 30% 
of T-ALL patients who relapsed demon-
strated lineage switch. The issue is hig-
hlighted here to show the heterogeneity 
of T-lymphoblast differentiation which, in 
this case evolved to B-lymphoblast at 
lineage conversion. This study also indi-
cated that lineage switch in acute leu-
kaemia was more common than might 
have been expected, possibly because of 
the wider use of intensive chemotherapy. 
More studies are needed to identify the 
target cells in leukaemogenesis to eva-
luate their spontaneous or drug induced 
capacity for lineage deviation and diffe-
rentiation, and to elucidate the relation-
ship between the genetic and phenotypic 
characteristics of leukaemic cell lineages. 
Prompt recognition of lineage switch 
may be helpful in selecting an effective 
therapeutic regimen. Ultimately, therapy 
appropriate for the leukaemic phenotype 
at the time of lineage switch may be ad-
visable.  
  
CONCLUSION 
 
Conversion of T-cell lineage ALL to B-cell 
lineage ALL is a rare occurrence. This case 
illustrated a phenotypic lineage switch from 
a characteristic T-ALL to common precursor 
B-ALL. In our case, lineage conversion 
occurred seven months after the initial 
diagnosis which was postulated to be likely 
due to chemotherapy which eradicated the 
dominant clone apparent at diagnosis, 
permitting expansion of a secondary clone 
with a different phenotype. Rapid 
recognition of this condition is needed to 
tailor treatment decision and strategy for 
disease monitoring. 
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